Gagan D. Singh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Gagan D. Singh has a total of 253 co-authors. Here are the top co-authors by number of shared publications:
- Jason H. Rogers
Division of Cardiovascular Medicine, University of California, Davis Medical Center, Sacramento, California, USA
14 shared publications Reginald I. Low
12 shared publications- Thomas W. Smith
Division of Cardiovascular Medicine, University of California, Davis Medical Center, Sacramento, California
12 shared publications Jason H. Rogers
10 shared publicationsBradley D. Stauber
University of California, Davis Medical Center
8 shared publicationsDali Fan
Division of Cardiovascular Medicine University of California Davis Davis California USA
7 shared publications
Latest Publications
- 5 May 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 19 (8) , e016010
Clinical Experience With a Novel Percutaneous LV Assist Device in High-Risk PCI: Primary Results From the SUPPORT I Study
BACKGROUND: An early feasibility study was conducted to evaluate the performance of a low-profile, microaxial percutaneous ventricular assist device (pVAD; Supira Medical, Los Gatos, CA) capable of up to 5.5 L/min flow to provide hemodynamic support in high-risk percutaneous coronary intervention. METHODS: A prospective, single-arm feasibility study using the Supira pVAD in high-risk percutaneous coronary intervention was performed at 4 centers in the United States. The primary feasibility end point was defined as successful initiation and maintenance of hemodynamic support without sustained hypotension or need for alternative mechanical circulatory support. The primary safety end point was the occurrence of major device-related adverse events attributed to the study device or procedure from the time of device insertion to removal. RESULTS: Fifteen patients underwent elective high-risk percutaneous coronary intervention with hemodynamic support using the Supira pVAD system. Multivessel percutaneous coronary intervention was performed in 80% of cases, including unprotected left main revascularization (67%) and atherectomy and intravascular lithotripsy (60%). Technical and procedural success rates were 93.3% and 86.7%, respectively. The primary feasibility end point was achieved in all 15 patients (100%). The primary safety end point occurred in 1 patient (6.7%). By 90 days, there were 2 deaths unrelated to the study device. There were no bleeding events, vascular/limb complications requiring intervention, cardiac structural/valve injury, or stroke attributed to the study device. CONCLUSIONS: As an early feasibility study, treatment with the Supira pVAD demonstrated favorable performance and device-related safety. These findings add to existing experience with the Supira pVAD to support a forthcoming pivotal trial in high-risk percutaneous coronary intervention. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT06087575.
- 5 May 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 19 (8) , e016010
Clinical Experience With a Novel Percutaneous LV Assist Device in High-Risk PCI: Primary Results From the SUPPORT I Study
BACKGROUND: An early feasibility study was conducted to evaluate the performance of a low-profile, microaxial percutaneous ventricular assist device (pVAD; Supira Medical, Los Gatos, CA) capable of up to 5.5 L/min flow to provide hemodynamic support in high-risk percutaneous coronary intervention. METHODS: A prospective, single-arm feasibility study using the Supira pVAD in high-risk percutaneous coronary intervention was performed at 4 centers in the United States. The primary feasibility end point was defined as successful initiation and maintenance of hemodynamic support without sustained hypotension or need for alternative mechanical circulatory support. The primary safety end point was the occurrence of major device-related adverse events attributed to the study device or procedure from the time of device insertion to removal. RESULTS: Fifteen patients underwent elective high-risk percutaneous coronary intervention with hemodynamic support using the Supira pVAD system. Multivessel percutaneous coronary intervention was performed in 80% of cases, including unprotected left main revascularization (67%) and atherectomy and intravascular lithotripsy (60%). Technical and procedural success rates were 93.3% and 86.7%, respectively. The primary feasibility end point was achieved in all 15 patients (100%). The primary safety end point occurred in 1 patient (6.7%). By 90 days, there were 2 deaths unrelated to the study device. There were no bleeding events, vascular/limb complications requiring intervention, cardiac structural/valve injury, or stroke attributed to the study device. CONCLUSIONS: As an early feasibility study, treatment with the Supira pVAD demonstrated favorable performance and device-related safety. These findings add to existing experience with the Supira pVAD to support a forthcoming pivotal trial in high-risk percutaneous coronary intervention. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT06087575.
- Open Access
- 7 April 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (7) , e044794
Clinical, Functional, and Quality‐of‐Life Outcomes After Contemporary Transcatheter Edge‐to‐Edge Repair for Primary Mitral Regurgitation in the Very Elderly
Background: Advanced age may influence the benefits derived from transcatheter edge‐to‐edge repair for primary mitral regurgitation (MR). We explored the impact of age on clinical, echocardiographic, functional, and patient‐reported outcomes after contemporary mitral transcatheter edge‐to‐edge repair. Methods: Patients with primary MR were identified from a pooled, patient‐level analysis of the EXPAND and EXPAND G4 studies. Key outcomes included 30‐day and 1‐year major adverse events, MR severity, New York Heart Association class, Kansas City Cardiomyopathy Questionnaire – Overall Summary score, and mortality. Results: A total of 854 patients were included. The oldest quartile ranged in age from 86 to 99 years, while the younger quartiles ranged from 21 to 85 years. The 30‐day major adverse events rate was not different in the oldest compared with the younger quartiles (5.7% versus 4.3%, P =0.46). At 1 year, MR ≤1+ was present in 81% of the oldest versus 88% of the younger patients ( P =0.08). LV end‐diastolic volumes improved to similar extent (−12.0±28.8 mL, P =0.003 and −14.1±31.5 mL, P P =0.34 across groups). Functional status and Kansas City Cardiomyopathy Questionnaire – Overall Score improved significantly across age groups, without differences according to age. Adjusted 1‐year mortality was higher in the oldest compared with the younger quartiles (adjusted hazard ratio 1.74 [95% CI, 1.02–2.98], P =0.04). Conclusions: Although 1‐year mortality was higher among the very elderly, mitral transcatheter edge‐to‐edge repair using next‐generation devices was associated with low complication rates and substantial improvements in ventricular remodeling, functional status, and quality of life across age groups. These findings support the use of mitral transcatheter edge‐to‐edge repair in appropriately selected elderly patients and suggest that age alone should not be a barrier to treatment.
- 7 April 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (7) , e044794
Open AccessClinical, Functional, and Quality‐of‐Life Outcomes After Contemporary Transcatheter Edge‐to‐Edge Repair for Primary Mitral Regurgitation in the Very Elderly
Background: Advanced age may influence the benefits derived from transcatheter edge‐to‐edge repair for primary mitral regurgitation (MR). We explored the impact of age on clinical, echocardiographic, functional, and patient‐reported outcomes after contemporary mitral transcatheter edge‐to‐edge repair. Methods: Patients with primary MR were identified from a pooled, patient‐level analysis of the EXPAND and EXPAND G4 studies. Key outcomes included 30‐day and 1‐year major adverse events, MR severity, New York Heart Association class, Kansas City Cardiomyopathy Questionnaire – Overall Summary score, and mortality. Results: A total of 854 patients were included. The oldest quartile ranged in age from 86 to 99 years, while the younger quartiles ranged from 21 to 85 years. The 30‐day major adverse events rate was not different in the oldest compared with the younger quartiles (5.7% versus 4.3%, P =0.46). At 1 year, MR ≤1+ was present in 81% of the oldest versus 88% of the younger patients ( P =0.08). LV end‐diastolic volumes improved to similar extent (−12.0±28.8 mL, P =0.003 and −14.1±31.5 mL, P P =0.34 across groups). Functional status and Kansas City Cardiomyopathy Questionnaire – Overall Score improved significantly across age groups, without differences according to age. Adjusted 1‐year mortality was higher in the oldest compared with the younger quartiles (adjusted hazard ratio 1.74 [95% CI, 1.02–2.98], P =0.04). Conclusions: Although 1‐year mortality was higher among the very elderly, mitral transcatheter edge‐to‐edge repair using next‐generation devices was associated with low complication rates and substantial improvements in ventricular remodeling, functional status, and quality of life across age groups. These findings support the use of mitral transcatheter edge‐to‐edge repair in appropriately selected elderly patients and suggest that age alone should not be a barrier to treatment.
- Open Access
- 1 February 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 19 (2) , e015883
Atrial Secondary Mitral Regurgitation Outcomes Following Mitral Transcatheter Edge-to-Edge Repair: Results From the EXPANDed Studies
BACKGROUND: Atrial secondary mitral regurgitation (aSMR) is a distinct subtype of SMR characterized by normal leaflets, annular dilatation, left atrial (LA) enlargement, and preserved left ventricular function. Treatment pathways for aSMR are undefined, and limited data exist regarding outcomes following mitral transcatheter edge-to-edge repair (MTEER). The analysis aimed to evaluate outcomes in patients with aSMR treated with MTEER from the EXPANDed (Evaluation of the MitraClip X System Post-MArket Real-World CliNical Outcomes Database ) studies. METHODS: One-year outcomes were assessed in patients from the EXPANDed studies (EXPAND and EXPAND G4 [Evaluation of the MitraClip X System Post-MArket Real-World CliNical Outcomes Database Generation 4 ]) who met criteria for aSMR. aSMR was defined by the presence of atrial fibrillation, left ventricular ejection fraction ≥45%, and at least 1 dilated LA parameter per echocardiographic core laboratory assessment: LA volume index, LA diameter, or LA diameter index. RESULTS: Of the 967 patients with SMR treated with MTEER in the EXPANDed data set, 160 (17%) met criteria for aSMR. Patients with aSMR were elderly (78±8 years), symptomatic (Kansas City Cardiomyopathy Questionnaire Overall Summary score, 48±27 pts), and had small left ventricular and large LA dimensions at baseline. Acute procedural success was achieved in 97.5% of patients with aSMR, with MR reduction to ≤1+ in 95.2% at 1 year. There were significant 1-year improvements in quality of life (+19 pt Kansas City Cardiomyopathy Questionnaire Overall Summary) and functional capacity (New York Heart Association I/II 80%). The 1-year all-cause mortality rate was 9%, with patients experiencing a 56% reduction in 1-year heart failure hospitalization rates from pre- to post-MTEER. CONCLUSIONS: In the largest population of patients with aSMR assessed by an echocardiographic core laboratory, MTEER safely and significantly reduced MR with improvements in quality of life and reduction in heart failure hospitalization through 1 year.
- 1 February 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 19 (2) , e015883
Open AccessAtrial Secondary Mitral Regurgitation Outcomes Following Mitral Transcatheter Edge-to-Edge Repair: Results From the EXPANDed Studies
BACKGROUND: Atrial secondary mitral regurgitation (aSMR) is a distinct subtype of SMR characterized by normal leaflets, annular dilatation, left atrial (LA) enlargement, and preserved left ventricular function. Treatment pathways for aSMR are undefined, and limited data exist regarding outcomes following mitral transcatheter edge-to-edge repair (MTEER). The analysis aimed to evaluate outcomes in patients with aSMR treated with MTEER from the EXPANDed (Evaluation of the MitraClip X System Post-MArket Real-World CliNical Outcomes Database ) studies. METHODS: One-year outcomes were assessed in patients from the EXPANDed studies (EXPAND and EXPAND G4 [Evaluation of the MitraClip X System Post-MArket Real-World CliNical Outcomes Database Generation 4 ]) who met criteria for aSMR. aSMR was defined by the presence of atrial fibrillation, left ventricular ejection fraction ≥45%, and at least 1 dilated LA parameter per echocardiographic core laboratory assessment: LA volume index, LA diameter, or LA diameter index. RESULTS: Of the 967 patients with SMR treated with MTEER in the EXPANDed data set, 160 (17%) met criteria for aSMR. Patients with aSMR were elderly (78±8 years), symptomatic (Kansas City Cardiomyopathy Questionnaire Overall Summary score, 48±27 pts), and had small left ventricular and large LA dimensions at baseline. Acute procedural success was achieved in 97.5% of patients with aSMR, with MR reduction to ≤1+ in 95.2% at 1 year. There were significant 1-year improvements in quality of life (+19 pt Kansas City Cardiomyopathy Questionnaire Overall Summary) and functional capacity (New York Heart Association I/II 80%). The 1-year all-cause mortality rate was 9%, with patients experiencing a 56% reduction in 1-year heart failure hospitalization rates from pre- to post-MTEER. CONCLUSIONS: In the largest population of patients with aSMR assessed by an echocardiographic core laboratory, MTEER safely and significantly reduced MR with improvements in quality of life and reduction in heart failure hospitalization through 1 year.
- 29 August 2025
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 47 (17) , 2059-2073
Tricuspid valve replacement outcomes by baseline tricuspid regurgitation severity: the TRISCEND II trial
Background and Aims: The TRISCEND II trial demonstrated superior clinical benefits for patients with ≥severe tricuspid regurgitation (TR) treated with the EVOQUE transcatheter tricuspid valve replacement (TTVR) system plus medical therapy vs medical therapy alone. This work reports 1-year and 18-month outcomes in patients stratified by baseline TR severity. Methods: The multicentre, prospective TRISCEND II trial enrolled 400 patients with symptomatic, ≥severe TR, and randomized 2:1 to TTVR (n = 267) or control (n = 133). In a post hoc analysis, patients were stratified into severe TR (n = 172) and massive/torrential TR (n = 220) cohorts. Clinical and quality-of-life outcomes were reported at 1 year, with Kaplan–Meier estimates for all-cause mortality and heart failure (HF) hospitalization assessed at 18 months. Study oversight included an independent echocardiographic core laboratory, clinical events committee, and data safety monitoring board. Results: One year after TTVR, TR was ≤mild in 95.2% of severe TR and 95.3% of massive/torrential TR patients. The primary safety and effectiveness endpoint (win ratio) favoured TTVR over control regardless of baseline TR severity: severe {1.64 [95% confidence interval (CI): 1.11, 2.43]} and massive/torrential [2.20 (1.55, 3.14)]. At 18 months, TTVR patients had similar mortality to controls [rate difference: severe 0.2% (−11.6, 11.9), massive/torrential −5.8% (−17.6, 6.0)], whereas HF hospitalization rates favoured TTVR in the massive/torrential cohort [vs control, severe 9.8% (−3.0, 22.7), massive/torrential -15.2% (−28.9, −1.5)]. Conclusions: Patients with ≥severe TR benefit from TTVR, experiencing improvements in TR severity, functional capacity, and quality of life regardless of baseline TR severity, with a signal for greater benefit in patients with more advanced disease.
- 29 August 2025
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 47 (17) , 2059-2073
Tricuspid valve replacement outcomes by baseline tricuspid regurgitation severity: the TRISCEND II trial
Background and Aims: The TRISCEND II trial demonstrated superior clinical benefits for patients with ≥severe tricuspid regurgitation (TR) treated with the EVOQUE transcatheter tricuspid valve replacement (TTVR) system plus medical therapy vs medical therapy alone. This work reports 1-year and 18-month outcomes in patients stratified by baseline TR severity. Methods: The multicentre, prospective TRISCEND II trial enrolled 400 patients with symptomatic, ≥severe TR, and randomized 2:1 to TTVR (n = 267) or control (n = 133). In a post hoc analysis, patients were stratified into severe TR (n = 172) and massive/torrential TR (n = 220) cohorts. Clinical and quality-of-life outcomes were reported at 1 year, with Kaplan–Meier estimates for all-cause mortality and heart failure (HF) hospitalization assessed at 18 months. Study oversight included an independent echocardiographic core laboratory, clinical events committee, and data safety monitoring board. Results: One year after TTVR, TR was ≤mild in 95.2% of severe TR and 95.3% of massive/torrential TR patients. The primary safety and effectiveness endpoint (win ratio) favoured TTVR over control regardless of baseline TR severity: severe {1.64 [95% confidence interval (CI): 1.11, 2.43]} and massive/torrential [2.20 (1.55, 3.14)]. At 18 months, TTVR patients had similar mortality to controls [rate difference: severe 0.2% (−11.6, 11.9), massive/torrential −5.8% (−17.6, 6.0)], whereas HF hospitalization rates favoured TTVR in the massive/torrential cohort [vs control, severe 9.8% (−3.0, 22.7), massive/torrential -15.2% (−28.9, −1.5)]. Conclusions: Patients with ≥severe TR benefit from TTVR, experiencing improvements in TR severity, functional capacity, and quality of life regardless of baseline TR severity, with a signal for greater benefit in patients with more advanced disease.
- Top Cited Papers
- 10 June 2025
- Published by Wolters Kluwer Health in Circulation
- Vol. 151 (23) , 1630-1638
Two-Year Outcomes of Transcatheter Edge-to-Edge Repair for Severe Tricuspid Regurgitation: The TRILUMINATE Pivotal Randomized Controlled Trial
BACKGROUND: One-year outcomes of TRILUMINATE Pivotal (Trial to Evaluate Cardiovascular Outcomes in Patients Treated With the Tricuspid Valve Repair System Pivotal) found that transcatheter edge-to-edge repair (TEER) for the treatment of severe, symptomatic tricuspid regurgitation improved quality of life compared with medical therapy alone with similar rates of mortality and heart failure hospitalization. However, additional follow-up is necessary to determine the prolonged benefits of tricuspid TEER. METHODS: A total of 572 patients with severe, symptomatic tricuspid regurgitation were randomized to either tricuspid TEER+medical therapy (device group) or medical therapy alone (control). Two-year prespecified end points were recurrent heart failure hospitalization and freedom from all-cause mortality, tricuspid valve surgery, and tricuspid valve intervention after treatment visit, assessed in the intention-to-treat population. RESULTS: The annualized rate of recurrent heart failure hospitalizations through 2 years was significantly lower with tricuspid TEER compared with control (0.19 event per patient-year versus 0.26 event per patient-year; P =0.02; joint frailty model hazard ratio, 0.72; one-sided upper confidence limit, 0.93; P =0.02). Freedom from all-cause mortality, tricuspid valve surgery, and tricuspid valve intervention through 2 years was significantly higher with tricuspid TEER compared with control (77.6% versus 29.3%; P <0.0001), driven by more tricuspid valve intervention in control patients who crossed over to device treatment (3.8% versus 61.5%). Rates of all-cause mortality (17.9% versus 17.1%) and tricuspid valve surgery (2.3% versus 4.3%) were similar between groups. Moderate or less tricuspid regurgitation was present in 84% at 2 years in the device group. CONCLUSIONS: At the 2-year follow-up, tricuspid TEER appeared safe, significantly reduced tricuspid regurgitation severity, and decreased rates of heart failure hospitalization compared with medical therapy alone. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03904147.
- 10 June 2025
- Published by Wolters Kluwer Health in Circulation
- Vol. 151 (23) , 1630-1638
Top Cited PapersTwo-Year Outcomes of Transcatheter Edge-to-Edge Repair for Severe Tricuspid Regurgitation: The TRILUMINATE Pivotal Randomized Controlled Trial
BACKGROUND: One-year outcomes of TRILUMINATE Pivotal (Trial to Evaluate Cardiovascular Outcomes in Patients Treated With the Tricuspid Valve Repair System Pivotal) found that transcatheter edge-to-edge repair (TEER) for the treatment of severe, symptomatic tricuspid regurgitation improved quality of life compared with medical therapy alone with similar rates of mortality and heart failure hospitalization. However, additional follow-up is necessary to determine the prolonged benefits of tricuspid TEER. METHODS: A total of 572 patients with severe, symptomatic tricuspid regurgitation were randomized to either tricuspid TEER+medical therapy (device group) or medical therapy alone (control). Two-year prespecified end points were recurrent heart failure hospitalization and freedom from all-cause mortality, tricuspid valve surgery, and tricuspid valve intervention after treatment visit, assessed in the intention-to-treat population. RESULTS: The annualized rate of recurrent heart failure hospitalizations through 2 years was significantly lower with tricuspid TEER compared with control (0.19 event per patient-year versus 0.26 event per patient-year; P =0.02; joint frailty model hazard ratio, 0.72; one-sided upper confidence limit, 0.93; P =0.02). Freedom from all-cause mortality, tricuspid valve surgery, and tricuspid valve intervention through 2 years was significantly higher with tricuspid TEER compared with control (77.6% versus 29.3%; P <0.0001), driven by more tricuspid valve intervention in control patients who crossed over to device treatment (3.8% versus 61.5%). Rates of all-cause mortality (17.9% versus 17.1%) and tricuspid valve surgery (2.3% versus 4.3%) were similar between groups. Moderate or less tricuspid regurgitation was present in 84% at 2 years in the device group. CONCLUSIONS: At the 2-year follow-up, tricuspid TEER appeared safe, significantly reduced tricuspid regurgitation severity, and decreased rates of heart failure hospitalization compared with medical therapy alone. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03904147.
- Open Access
- 9 December 2024
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 17 (23) , 2749-2760
Transcatheter Edge-to-Edge Repair in Patients With Complex Tricuspid Valve Anatomy
- 9 December 2024
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 17 (23) , 2749-2760
Open AccessTranscatheter Edge-to-Edge Repair in Patients With Complex Tricuspid Valve Anatomy
- Open Access
- 23 October 2024
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 17 (21) , 2530-2540
Combined Impact of Residual Mitral Regurgitation and Gradient After Mitral Valve Transcatheter Edge-to-Edge Repair
- 23 October 2024
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 17 (21) , 2530-2540
Open AccessCombined Impact of Residual Mitral Regurgitation and Gradient After Mitral Valve Transcatheter Edge-to-Edge Repair
- Open Access
- 7 August 2024
- Published by Elsevier in JACC: Case Reports
- Vol. 29 (15) , 102443
Transcatheter Extraction of a Migrated Left Atrial Appendage Occluder Device
- 7 August 2024
- Published by Elsevier in JACC: Case Reports
- Vol. 29 (15) , 102443
Open AccessTranscatheter Extraction of a Migrated Left Atrial Appendage Occluder Device
- 3 October 2023
- Published by Elsevier in Interventional Cardiology Clinics
- Vol. 13 (1) , 11-17
3D Intracardiac Echocardiography for Structural Heart Interventions
- 3 October 2023
- Published by Elsevier in Interventional Cardiology Clinics
- Vol. 13 (1) , 11-17
3D Intracardiac Echocardiography for Structural Heart Interventions